Contact Information

Photo of Mark Albertini
Mark Albertini, MD



MADISON, WI 53792-0001

(608) 263-0117


Mark R. Albertini received his MD from the University of Vermont and did his residency training in Internal Medicine at the University of Wisconsin Hospital and Clinics. Following his residency, he completed two years of postdoctoral fellowship training in Tumor Immunology at the University of Wisconsin-Madison. He subsequently completed fellowships in Medical Oncology and Biotherapy at the UW Comprehensive Cancer Center. He is Board Certified in Internal Medicine and Medical Oncology. He was appointed Assistant Professor in July 1, 1993 and was promoted to Associate Professor with tenure on July 1, 1999.

Dr. Albertini's research efforts are focused on melanoma and the development of immunotherapeutic approaches to this disease. The overall goal of his translational melanoma research program is to provide an understanding of the immunobiology of human malignant melanoma as a means to develop an effective immunotherapy for patients with this disease. This goal is pursued with clinical and laboratory studies involving patients receiving novel immunotherapies and with preclinical model systems to direct subsequent studies.

Dr. Albertini established the University of Wisconsin Comprehensive Cancer Center Comprehensive Melanoma Clinic in September of 1994. The goals of this clinic are 1) to provide comprehensive and innovative treatment approaches for patients with melanoma; 2) to provide a mechanism for coordination of clinical and laboratory research in the field of melanoma for advanced disease, adjuvant studies, and high risk lesions; and 3) to provide optimal patient care and coordination of services. Dr. Albertini is actively involved in protocol development of immunotherapy protocols for patients with melanoma. He has been protocol chairman for studies investigating chemotherapy, cytokines, monoclonal antibodies, immunocytokines, and DNA vaccines. He directs a laboratory research program that is investigating DNA vaccines as a potential treatment to bring to the clinic.

Search for Mark Albertini's literature abstracts on PubMed

Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer R, Storer B, Reisfeld RA, Sondel PM. A phase IB trial of chimeric anti-GD2 antibody plus interleukin-2 for melanoma patients. Clinical Cancer Research, 1277-1288, 1997.

McCarthy, DO, Glowacki, N, Schell, K, Emler, CA, Albertini, MR. Antigenicity of Human Melanoma Cells Transfected to Express the B7-1 Costimulatory Molecule (CD80) Varies with the Level of B7-1 Expression. Cancer Immunology and Immunotherapy, 49:85-93, 2000.

Eastman, ME, Khorsand, M, Maki, D, Williams, E, Kim, KM, Sondel, P, Schiller, JH, Albertini, MR. Central Venous Device-Related Infection and Thrombosis in Patients Treated with Moderate-Dose Continuous-Infusion Interleukin-2. Cancer, 91:806-814, 2001.

Albertini, MR, King, DM, Newton, MA, and Vacek, PM. In Vivo Mutant Frequency of Thioguanine-Resistant T-cells in the Peripheral Blood and Lymph Nodes of Melanoma Patients. Mutation Research, 476:83-97, 2001.

Rakhmilevich, AL, Imboden, M, Hao, Z, Macklin, MD, Roberts, T, Wright, KM, Albertini, MR, Yang, NS, Sondel, PM. Effective particle-mediated vaccination against mouse melanoma by co-administration of plasmid DNA encoding gp100 and granulocyte-macrophage colony stimulating factor. Clinical Cancer Research, 7: 952-961, 2001.